Mandatory certification for clozapine prescribing

摘要

Clozapine is the only registered treatment for therapy-resistant schizophrenia (meaning, after treatment with two other antipsychotics failed or were not tolerated), psychosis in Parkinson’s disease, and, in the United States, for suicidality. Off-label, clozapine is prescribed for therapy-resistant disorders, especially therapy-resistant bipolar, borderline personality, violent behavior, or self-harm in patients with psychosis, aggressive behavior, or addiction to cannabis in psychotic disorder and in the animal model.